Lineage Cell Therapeutics Q3 2026: EPS Beat Masks Revenue Slide

As seen on the 24/7 Wall St. homepage on November 12, 2026.

LCTX Lineage Cell Therapeutics
Q3 2026
EPS
-$0.03
est -$0.04 +14.3%
Revenue
$1M
est $2M -27.8%

Collaboration revenue fell 61% from a year ago as Roche deferred revenue winds down, missing expectations, and the earnings beat rests on a non-cash warrant gain. The NeuroAirmid deal closing adds Huntington's cell therapy HUNT1 as a third clinical asset, with $45.2 million in cash funding operations into Q2 2028.

Continue ReadingShow less

Lineage Cell Therapeutics reported a loss of $0.03 per share for Q3 2026, edging past the consensus estimate of a $0.035 loss. The beat rests almost entirely on a non-cash gain from the remeasurement of warrant liabilities, so the headline number flatters the underlying business.

Revenue of $1.43 million fell 61% from a year ago, missing expectations. The decline reflects the ongoing wind-down of deferred revenue recognized from the Roche collaboration, as well as lower billings under the WDI research arrangement.

Sponsored

Lineage closed the NeuroAirmid Therapeutics acquisition on the same day it filed results, adding HUNT1, a pluripotent stem cell-derived neural cell therapy in a Phase 1b/2a study for Huntington's Disease, as its third clinical-stage asset. Lineage paid roughly $4.70 million at closing, with up to $48 million in additional milestone payments. The California Institute for Regenerative Medicine is covering the majority of clinical costs for the ongoing REGEN4HD study.

Lineage held $45.2 million in cash and securities as of September 30, 2026, which management says funds planned operations into Q2 2028. Initial preclinical data from the COR1 corneal endothelial cell therapy program is expected in Q1 2027, and a meeting with the Danish Medicines Agency on the ReSonance hearing-loss program is scheduled for Q4 2026.

Mentioned: LCTX